2/6
08:42 am
aclx
Arcellx (ACLX) Declined Despite Positive Clinical Trial Results [Yahoo! Finance]
Low
Report
Arcellx (ACLX) Declined Despite Positive Clinical Trial Results [Yahoo! Finance]
2/5
08:04 am
aclx
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.
Medium
Report
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.
2/4
01:16 pm
aclx
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.
Low
Report
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.
2/4
09:00 am
aclx
Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel’s D-Domain Binder
Low
Report
Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel’s D-Domain Binder
2/3
01:41 am
aclx
Assessing Arcellx (ACLX) Valuation After Recent Share Price Swings And Conflicting P/B And DCF Signals [Yahoo! Finance]
Low
Report
Assessing Arcellx (ACLX) Valuation After Recent Share Price Swings And Conflicting P/B And DCF Signals [Yahoo! Finance]
2/2
10:40 pm
aclx
Is Arcellx (ACLX) Still Attractively Priced After Strong Multi Year Share Price Gains [Yahoo! Finance]
Low
Report
Is Arcellx (ACLX) Still Attractively Priced After Strong Multi Year Share Price Gains [Yahoo! Finance]
1/31
10:17 pm
aclx
Arcellx Director Sells 6,000 Shares for $450,000 [Yahoo! Finance]
Low
Report
Arcellx Director Sells 6,000 Shares for $450,000 [Yahoo! Finance]
1/30
12:53 am
aclx
UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect [Yahoo! Finance]
Low
Report
UBS Initiates Coverage of Arcellx With Bullish Outlook as Biotech Fundamentals Inflect [Yahoo! Finance]
1/23
05:06 am
aclx
Arcellx (NASDAQ:ACLX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Arcellx (NASDAQ:ACLX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/21
04:14 pm
aclx
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings [Yahoo! Finance]
Low
Report
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings [Yahoo! Finance]
1/21
04:00 pm
aclx
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings
Low
Report
Arcellx to Advance the Conversation on Its Platform and the Importance of Early CAR T Access for Patients with Multiple Myeloma During the 2026 Tandem Meetings
1/7
10:02 am
aclx
Arcellx (NASDAQ:ACLX) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Medium
Report
Arcellx (NASDAQ:ACLX) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
1/7
04:06 am
aclx
Arcellx (NASDAQ:ACLX) was given a new $100.00 price target on by analysts at UBS Group AG.
Medium
Report
Arcellx (NASDAQ:ACLX) was given a new $100.00 price target on by analysts at UBS Group AG.
12/24
07:01 pm
aclx
Arcellx (ACLX) Valuation Check After Wells Fargo Launches Coverage on Its Multiple Myeloma CAR-T Program [Yahoo! Finance]
Low
Report
Arcellx (ACLX) Valuation Check After Wells Fargo Launches Coverage on Its Multiple Myeloma CAR-T Program [Yahoo! Finance]
12/24
06:15 am
aclx
Arcellx (NASDAQ:ACLX) was upgraded by analysts at Wells Fargo & Company to a "strong-buy" rating.
Low
Report
Arcellx (NASDAQ:ACLX) was upgraded by analysts at Wells Fargo & Company to a "strong-buy" rating.
12/22
05:01 am
aclx
Arcellx (NASDAQ:ACLX) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating on the stock.
Low
Report
Arcellx (NASDAQ:ACLX) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating on the stock.
12/17
08:24 am
aclx
Arcellx: Funded Into 2028 With Strong Clinical Data [Seeking Alpha]
Low
Report
Arcellx: Funded Into 2028 With Strong Clinical Data [Seeking Alpha]
12/8
01:20 pm
aclx
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $130.00 price target on the stock.
Medium
Report
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $130.00 price target on the stock.
12/8
08:07 am
aclx
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.
Medium
Report
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.
12/6
02:24 pm
aclx
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma [Yahoo! Finance]
Medium
Report
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma [Yahoo! Finance]
12/6
02:24 pm
aclx
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma [Yahoo! Finance]
Medium
Report
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma [Yahoo! Finance]
12/6
02:00 pm
aclx
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
Medium
Report
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
11/30
05:51 am
aclx
CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting [Yahoo! Finance]
Medium
Report
CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting [Yahoo! Finance]
11/24
03:08 pm
aclx
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
11/24
03:08 pm
aclx
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Guggenheim.